Lianhuan Pharmaceutical completes investment in Chang Le Pharmaceutical

Jiangsu Lianhuan Pharmaceutical (SSE:600513) announced the completion of its investment in Xinxiang City Chang Le Pharmaceutical, as well as associated industrial and commercial registration changes. The company secured a 49% equity stake in Chang Le Pharmaceutical through a RMB 18,326,000 investment. The acquisition was initially approved at the company’s Ninth Board of Directors Sixth Interim Meeting on January 22, 2025. Post-transaction, Chang Le Pharmaceutical's registered capital remains at RMB 3,958,000, with Jiangsu Lianhuan Pharmaceutical holding 49% of the shares, Li Donghong holding 46%, and Xinxiang City Construction Investment Co., Ltd holding the remaining 5%. The updated business license has been issued by the Huixian City Market Supervision and Administration Bureau.